非洲儿童和青少年接种2剂异源Ad26.ZEBOV、MVA-BN-Filo埃博拉疫苗的安全性和免疫原性:一项随机、安慰剂对照、多中心II期临床试验
该多中心、随机、观察者盲、安慰剂对照II期试验在非洲入组131名青少年(12-17岁)和132名儿童(4-11岁),按5:1随机接种Ad26.ZEBOV和MVA-BN-Filo(间隔28或56天)或安慰剂。未报告疫苗相关严重不良事件,所有接种者均产生抗EBOV GP抗体,56天间隔组几何平均浓度更高,体液应答至少持续至第365天。
要点
- 2剂异源Ad26.ZEBOV、MVA-BN-Filo方案在非洲青少年和儿童中耐受良好,未报告疫苗相关严重不良事件。
- 所有接种者在第2剂后21天均产生抗EBOV GP结合抗体,56天间隔组几何平均浓度高于28天间隔组。
- 儿童接种后发热频率高于青少年。
核心结论
- 2剂异源疫苗接种在非洲青少年和儿童中耐受良好,未报告疫苗相关严重不良事件。
- 所有接种者在2剂方案后均显示抗EBOV GP抗体,56天间隔组应答更高。
- 儿童接种疫苗或安慰剂后发热频率高于青少年。
- 这些数据支持该疫苗在儿童人群中的预防性适应证,并已在欧盟获批。
研究设计与样本
- 多中心、随机、观察者盲、安慰剂对照II期研究,在东部和西部非洲入组131名青少年(12至17岁)和132名儿童(4至11岁),按5:1随机分配。
- 疫苗组肌肉注射Ad26.ZEBOV(5×10^10病毒颗粒)和MVA-BN-Filo(1×10^8感染单位),间隔28或56天;安慰剂组注射生理盐水。
- 主要结局为安全性和耐受性;次要和探索性结局为至首剂后1年的体液免疫应答。
- 入组开始于2016年2月26日,末例受试者末次访视日期为2018年11月28日。
主要发现
- 263名入组者中,217名(109名青少年、108名儿童)接受2剂方案,43名(20名青少年、23名儿童)接受2剂安慰剂。
- 青少年中位年龄14.0岁(范围11至17岁),儿童7.0岁(范围4至11岁);青少年54%和儿童51%为男性。
- 未报告疫苗相关严重不良事件;征集性不良事件多为轻/中度。
- MVA-BN-Filo接种后21天,100%接种者(106名青少年、104名儿童)观察到抗EBOV GP结合抗体应答。
- 几何平均浓度在56天间隔组倾向于更高(青少年13,532 EU/mL,儿童17,388 EU/mL) than 28天间隔组(青少年6,993 EU/mL,儿童8,007 EU/mL);体液应答至少持续至第365天。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 随访期对大多数参与者限于365天,因此无法确定免疫应答是否持续超过该时间段。
- 正式的统计学比较未预先计划,仅在事后进行。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Reoccurring Ebola outbreaks in West and Central Africa have led to serious illness and death in thousands of adults and children. The objective of this study was to assess safety, tolerability, and immunogenicity of the heterologous 2-dose Ad26.ZEBOV, MVA-BN-Filo vaccination regimen in adolescents and children in Africa. METHODS AND FINDINGS: In this multicentre, randomised, observer-blind, placebo-controlled Phase II study, 131 adolescents (12 to 17 years old) and 132 children (4 to 11 years old) were enrolled from Eastern and Western Africa and randomised 5:1 to receive study vaccines or placebo. Vaccine groups received intramuscular injections of Ad26.ZEBOV (5 × 1010 viral particles) and MVA-BN-Filo (1 × 108 infectious units) 28 or 56 days apart; placebo recipients received saline. Primary outcomes were safety and tolerability. Solicited adverse events (AEs) were recorded until 7 days after each vaccination and serious AEs (SAEs) throughout the study. Secondary and exploratory outcomes were humoral immune responses (binding and neutralising Ebola virus [EBOV] glycoprotein [GP]-specific antibodies), up to 1 year after the first dose. Enrolment began on February 26, 2016, and the date of last participant last visit was November 28, 2018. Of the 263 participants enrolled, 217 (109 adolescents, 108 children) received the 2-dose regimen, and 43 (20 adolescents, 23 children) received 2 placebo doses. Median age was 14.0 (range 11 to 17) and 7.0 (range 4 to 11) years for adolescents and children, respectively. Fifty-four percent of the adolescents and 51% of the children were male. All participants were Africans, and, although there was a slight male preponderance overall, the groups were well balanced. No vaccine-related SAEs were reported; solicited AEs were mostly mild/moderate. Twenty-one days post-MVA-BN-Filo vaccination, binding antibody responses against EBOV GP were observed in 100% of vaccinees (106 adolescents, 104 children). Geometric mean concentrations tended to be higher after the 56-day interval (adolescents 13,532 ELISA units [EU]/mL, children 17,388 EU/mL) than the 28-day interval (adolescents 6,993 EU/mL, children 8,007 EU/mL). Humoral responses persisted at least up to Day 365. A limitation of the study is that the follow-up period was limited to 365 days for the majority of the participants, and so it was not possible to determine whether immune responses persisted beyond this time period. Additionally, formal statistical comparisons were not preplanned but were only performed post hoc. CONCLUSIONS: The heterologous 2-dose vaccination was well tolerated in African adolescents and children with no vaccine-related SAEs. All vaccinees displayed anti-EBOV GP antibodies after the 2-dose regimen, with higher responses in the 56-day interval groups. The frequency of pyrexia after vaccine or placebo was higher in children than in adolescents. These data supported the prophylactic indication against EBOV disease in a paediatric population, as licenced in the EU. TRIAL REGISTRATION: ClinicalTrials.gov NCT02564523.
引用
- Anywaine Z, Barry H, Anzala O, et al. Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial. PLoS Med. 2022. PMID: 35015777. doi:10.1371/journal.pmed.1003865
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。